Otsuka Pharmaceutical Factory, Inc.

Adabio Co., Ltd.

Katsuya Hiraishi

Ippei Yamaoka

Hiroyuki Soma

Fumie Jimma

Taro Adachi

Masakazu Adachi

Tomohiro Kagawa

Naoyuki Endo

By using ion exchange column chromatography or calcium carbonate to an aqueous solution containing a compound A represented by the following formula and citric acid, citric acid in the aqueous solution is removed and a crystalline compound A is obtained by being thereafter subjected to several steps. Further a high-purity noncrystalline compound A is obtained by using calcium carbonate, sulfuric acid, an organic solvent and the like to the aqueous solution containing the compound A and citric acid to remove citric acid and the crystalline compound A in the solution. The configuration of the crystalline compound A is an SS isomer in the RS notation system. The configuration of the noncrystalline compound A is an SR isomer. 

Method for manufacturing diastereomer of citric acid derivative

Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein Rrepresents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and Rrepresents a hydrogen atom, or Rand Roptionally form a cyclic structure together to represent a C2 to C3 alkylene chain). 

Citric acid derivative

The present invention provides a prophylactic and/or therapeutic agent for non-alcoholic fatty liver disease (NAFLD), and particularly non-alcoholic steatohepatitis (NASH) comprising an ume (Japanese apricot) juice concentrate or a processed product thereof. The prophylactic and/or therapeutic agent is obtained by utilizing a component contained in a plant or a processed product thereof, and hence is safe and easily taken. It has been confirmed that when the ume juice concentrate or the processed product thereof is orally administered to a streptozocin (STZ)-induced NAFLD model mouse or an STZ-induced NASH model mouse, liver fibrogenesis can be reduced.

Prophylactic and/or therapeutic agent for NAFLD/NASH

Growing community of inventors

Gunma, Japan

Katsuya Hiraishi